Clinical Trials

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT03580655 2026-04-24

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

107 enrolled 30 charts 1 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT03401060 2026-03-31

DenosuMast

Phase 3 Completed

24 enrolled

Osteoporosis, Mastocytosis, Systemic

NCT06748001 2026-02-09

Avapritinib Rollover Study

Phase 4 Recruiting

60 enrolled

Mastocytosis, Systemic

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

13 enrolled

Phase 2 Active not recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03731260 2025-09-23

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

251 enrolled

Mastocytosis, Systemic

NCT00769587 2025-09-22

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed

MyeloidOther neoplasm

Precancerous Conditions, Mastocytosis, Systemic

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

10 enrolled 4 charts

Mastocytosis, Systemic

NCT05609942 2025-04-10

AZURE

Phase 1 Terminated

9 enrolled

Leukemia, Mast-Cell, Mastocytosis, Systemic, Myelodysplastic-Myeloproliferative Diseases

NCT03770273 2024-12-17

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

21 enrolled 13 charts

Mastocytosis, Systemic

NCT04655118 2024-05-10

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Phase 2 Unknown

121 enrolled

Mastocytosis, Systemic, Primary Myelofibrosis

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

282 enrolled

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase 3 Unknown

140 enrolled

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

86 enrolled 1 FDA

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Phase 1/2 Terminated

12 enrolled 20 charts

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Phase 1/2 Completed

507 enrolled 16 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03739606 2020-12-17

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Phase 2 Withdrawn

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00814073 2019-12-03

AB06006

Phase 3 Completed

135 enrolled

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT02441166 2019-07-15

EvaTryMS

Phase NA Completed

250 enrolled

DermatologicMyeloid

Mastocytosis, Cutaneous, Mastocytosis, Systemic

NCT02808793 2019-03-13

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

25 enrolled

Mastocytosis, Mastocytosis, Systemic

NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

10 enrolled 14 charts

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

116 enrolled 16 charts

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

26 enrolled 12 charts

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Phase 2 Terminated

4 enrolled 14 charts

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes